Mustafa Öztürk

Mustafa Öztürk

Auto-generated profile, based on publicly available information

Mustafa Öztürk

Department of Cardiology, Faculty of Medicine Trabzon University Trabzon Turkey

Research Focus & Metrics

Academic Career Length

13Years (2014-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
17 August 2022 in Angiology
Verified
Journal Article
Closed access
EAEmrah AKSAKAL
Emrah AKSAKAL
UAUğur Aksu
Uğur Aksu
OBOğuzhan Birdal
Oğuzhan Birdal
MÖMustafa Öztürk
Mustafa Öztürk
OGOktay Gülcü
Oktay Gülcü
MLMerve Lazoğlu
Merve Lazoğlu
Many complications can be observed after ST-elevation myocardial infarction (STEMI). The systemic immune-inflammatory index (SII) is a sensitive indicator of the inflammatory state, and this parameter may also be associated with cardiovascular diseases. In this study, we investigated the relationship between malignant ventricular arrhythmias (MVA) development and SII in STEMI patients. A total of 1708 STEMI patients were included in the study. Propensity score matching (PSM) analysis was performed. Patients were divided into 2 groups according to the development of MVA, and predictors of MVA development were investigated. After the PSM analysis, the mean age of 158 patients was 61.6 years, and 68.4% were male. In the univariate analysis, neutrophil count, SII, C-reactive protein (CRP), albumin, and CRP/albumin ratio (CAR) were associated with the development of MVA; while in the regression analysis, CAR and SII was found to be independent predictors of the development of MVA. In this study, we demonstrated that SII is a better independent predictor than other inflammatory parameters for predicting the development of MVA. This index may be useful in clinical use.

Verified
Journal Article
Open access
PDF file
Emrah IpekEmrah Ipek
Emrah Ipek
MYMustafa Yolcu
Mustafa Yolcu
EYErkan Yildirim
Erkan Yildirim
KAKonca Altinkaynak
Konca Altinkaynak
SSSaime Ozbek Sebin
Saime Ozbek Sebin
MOMustafa Ozturk
Mustafa Ozturk
(1) To investigate the role of azurocidin, an antimicrobial protein, in patients with ST segment elevation myocardial infarction (STEMI). (2) This single-center prospective observational study included patients with STEMI and healthy age- and sex-matched control subjects. Baseline demographic, clinical and biochemical data were compared between the two groups. Azurocidin levels at baseline were determined using an enzyme-linked immunosorbent assay. Multivariate linear regression analysis with enter method was used to test the association between azurocidin and independent variables, such as the thrombolysis in myocardial infarction (TIMI) score, synergy between percutaneous coronary intervention with TAXUS and cardiac surgery score, global registry of acute coronary events score, Killip class, C-reactive protein (CRP), and creatinine kinase-myocardial band (CK-MB). (3) A total of 76 patients with STEMI and 30 healthy control subjects were enrolled in the study. Mean ± SD azurocidin levels were significantly higher in patients compared with healthy controls (18.07 ± 13.99 versus 10.09 ± 5.29 ng/mL, respectively). In a receiver-operating characteristic curve analysis, an azurocidin cut-off level of >11.46 ng/mL had 74% sensitivity and 58% specificity in predicting myocardial infarction. Azurocidin levels had a positive correlation with TIMI score (r = 0.651). In multivariate linear regression analysis, the TIMI score was an independent predictor of the azurocidin level. (4) Azurocidin is an infection marker that may be important in patients with STEMI.

21 December 2018 in Journal of Electrocardiology
Verified
Journal Article
Closed access
MÖMustafa Öztürk
Mustafa Öztürk
OTOğuzhan Ekrem Turan
Oğuzhan Ekrem Turan
KKKayıhan Karaman
Kayıhan Karaman
NBNuray Bilge
Nuray Bilge
GCGökhan Ceyhun
Gökhan Ceyhun
SDSelami Demirelli
Selami Demirelli

18 July 2016 in Angiology
Verified
Journal Article
Closed access
MOMustafa Ozturk
Mustafa Ozturk
LALutfu Askın
Lutfu Askın
Emrah IpekEmrah Ipek
Emrah Ipek
SDSelami Demirelli
Selami Demirelli
OTOguzhan Ekrem Turan
Oguzhan Ekrem Turan
ODOrhan Delice
Orhan Delice
Data are scant regarding serum bilirubin levels in non-ST-segment elevation acute coronary syndrome (NSTE-ACS). In this study, we evaluated the role of serum bilirubin levels in NSTE-ACS. We enrolled 782 patients who presented to the emergency department with acute chest pain. Patients were divided into 2 groups based on the troponin positivity. Patients with NSTE-ACS who had troponin positivity were included in group 1 (n = 382), and group 2 consisted of the control patients (n = 400). Direct bilirubin (DB) levels (group 1: 0.31 ± 0.37 mg/dL, group 2: 0.20 ± 0.25 mg/dL, P < .001) and total bilirubin (TB) levels (group 1: 0.78 ± 0.56 mg/dL, group 2: 0.62 ± 0.45 mg/dL, P < .001) were significantly higher in group 1. There was a significant and moderate correlation between serum bilirubin levels and admission troponin values (r = .34, P < .001 for TB and r = .42, P < .001 for DB). These results show that serum bilirubin levels were associated with troponin positivity in patients with NSTE-ACS.

2 June 2021 in Journal of Thrombosis and Thrombolysis
Verified
Journal Article
Closed access
PDF file
OGOktay Gülcü
Oktay Gülcü
EAEmrah AKSAKAL
Emrah AKSAKAL
SASelim Aydemir
Selim Aydemir
RDRemziye Doğan
Remziye Doğan
İSİbrahim Saraç
İbrahim Saraç
İTİbrahim Halil Tanboğa
İbrahim Halil Tanboğa

15 January 2014
Verified
Journal Article
Closed access
OGOmer Gedikli
Omer Gedikli
MOMustafa Ozturk
Mustafa Ozturk
OTOguzhan Ekrem Turan
Oguzhan Ekrem Turan
AIAbdusselam Ilter
Abdusselam Ilter
YHYusuf Hosoglu
Yusuf Hosoglu
GKGulhanim Kiris
Gulhanim Kiris